Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.
The use of docetaxel may lead to udesired outcomes such as hepatic impairment, hematologic effects, enterocolitis and neutropenic colitis, hypersensitivity reactions, fluid retention, second primary malignancies, embryo-fetal toxicity, and tumor lysis syndrome. Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. For the treatment of metastatic castration-resistant prostate cancer, docetaxel is indicated with prednisone. Docetaxel is also indicated with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction, and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Hospital Mae de Deus, Porto Alegre, Brazil
Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03, Porto Alegre, Brazil
Birmingham Heartlands Hospital,Substudy-03, Birmingham, United Kingdom
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Cancer Hospital,Chinese Academy of Medical Sciences, Beijing, China
The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California, United States
Local Institution - 0019, Los Angeles, California, United States
Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina
Washington University School of Medicine, Saint Louis, Missouri, United States
Inova Schar Cancer Institute, Fairfax, Virginia, United States
Baylor College of Medicine, Houston, Texas, United States
Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas, United States
Baylor St. Luke's Medical Center, Houston, Texas, United States
GSK Investigational Site, Uppsala, Sweden
Shanghai East Hospital, Shanghai, China
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
Local Institution - 0096, Costa Mesa, California, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.